Biodexa Pharmaceuticals Plc

Biodexa Pharmaceuticals develops eRapa, an oral rapamycin formulation for familial adenomatous polyposis and non-muscle invasive bladder cancer; MTX240, a molecular glue for gastrointestinal stromal tumors; and tolimidone, a Lyn kinase inhibitor for type 1 diabetes.